Zura Bio Investor Relations Material
Latest events
Corporate Presentation
2 Sep, 2025
Q2 2025
14 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Zura Bio Limited
Access all reports
Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. It leverages multi-asset immunology to create novel dual-pathway antibodies, including tibulizumab, ZB-168, and torudokimab, which are designed to address autoimmune diseases and other conditions with unmet medical needs. These therapies have completed early-phase studies and are advancing towards further clinical development. Zura Bio Limited is headquartered in Henderson, Nevada, and its shares are listed on NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ZURA
Country
🇺🇸 United States